Daily Cosmetic Research Analysis
Analyzed 8 papers and selected 3 impactful papers.
Summary
A multicentre randomized trial in Lancet challenges routine surgical reduction for severely displaced pediatric distal radius fractures, finding only small, transient functional benefits versus cast-first care with higher costs and more early complications. Complementing clinical insights, a materials study introduces a permeable Janus cellulose electrode that improves fluid-to-sensor interfacing for wearable biosensors, and a toxicology study identifies carboxylesterase 2 as a molecular target inhibited by long-chain PFCAs, informing safety of PFAS exposures including cosmetics.
Research Themes
- Pragmatic pediatric RCTs redefining surgical indications and cosmetic considerations
- Skin-integrated biosensing via permeable cellulose electronics
- PFAS mechanistic toxicology impacting drug metabolism and cosmetic safety
Selected Articles
1. Non-surgical casting versus surgical reduction for children with severely displaced distal radial fractures (the CRAFFT Study): a multicentre, randomised, controlled non-inferiority trial and economic evaluation.
In 750 children with severely displaced distal radius fractures, surgical reduction yielded a small 3-month functional advantage versus cast-first care that did not meet a conservative non-inferiority margin and did not persist. Surgical treatment incurred higher costs and more early complications, supporting a cast-first strategy for most children, with non-inferiority consistent in completely off-ended fractures under a wider margin.
Impact: This pragmatic, registered multicentre RCT with an economic evaluation directly informs practice by quantifying functional, safety, cosmetic, and cost trade-offs between surgery and casting in a common pediatric injury.
Clinical Implications: Adopt a cast-first approach for most 4–10-year-old children with severely displaced distal radius fractures, reserving surgery for select indications, given small, transient functional gains from surgery, higher early complications, and inferior cost-effectiveness.
Key Findings
- At 3 months, PROMIS Upper Extremity scores were 44.9 (cast) vs 46.6 (surgery); adjusted mean difference −1.64 (95% CI −2.84 to −0.44), not meeting the −2.5 non-inferiority margin.
- In completely off-ended fractures, results were consistent with non-inferiority against a prespecified wider margin (−5 points).
- Early complications were more frequent after surgery (pressure damage n=2, wound infections n=6, scarring n=5, nerve irritation n=1).
- Casting reduced mean NHS/PSS cost per patient by £1665 with marginal QALY reduction (−0.023), yielding a 100% probability of cost-effectiveness at £20–30k/QALY.
Methodological Strengths
- Pragmatic multicentre randomized non-inferiority design with prespecified subgroup and intention-to-treat analysis.
- Parallel within-trial economic evaluation from the NHS/PSS perspective.
Limitations
- Participants and families were unblinded, which may influence patient-reported outcomes.
- Conservative non-inferiority margin and treatment heterogeneity (fixation at surgeon discretion).
Future Directions: Define criteria for surgical selection (e.g., instability predictors), assess long-term cosmesis and function at 3 years, and explore shared decision-making tools contextualizing the small early benefits versus risks and costs.
BACKGROUND: Severely displaced distal radial fractures are among the most common and controversial injuries in children. Despite observational evidence of reliable remodelling with growth in younger children, their alarming radiographic appearance-particularly when completely displaced (off-ended)-has driven routine surgical reduction and fixation. The Children's Radius Acute Fracture Fixation Trial (CRAFFT) aimed to evaluate the clinical and cost-effectiveness of surgical reduction compared with non-surgical casting. METHODS: This pragmatic, multicentre, randomised, non-inferiority trial included participants (aged 4-10 years) with a severely displaced distal radial fracture from 49 hospitals in the UK. Recruiting centres were secondary or tertiary care hospitals providing acute paediatric trauma care. Participants were randomly assigned to either non-surgical casting or surgical reduction, using a minimisation algorithm with a random element and stratification factors were centre, age group, fracture location, and displacement severity. Participants and their parents and carers could not be masked to treatment. Surgical reduction was performed under general anaesthesia or conscious sedation, to restore anatomical alignment, with fixation permitted at the discretion of the surgeon. Non-surgical care involved immobilisation of the fracture in a plaster cast without general anaesthesia or sedation, and without purposeful manipulation of the fracture position. Immobilisation of the fracture beyond 6 weeks post-randomisation was not recommended. The primary outcome was upper limb function at 3 months, measured using the Patient Report Outcomes Measurement System (PROMIS) Upper Extremity Score for Children in the intention-to-treat population, which included all participants in the groups to which they were randomly assigned, irrespective of treatment received. The non-inferiority margin was conservatively set at -2·5 points for the main trial population. A prespecified subgroup analysis was powered to assess whether non-surgical casting could exclude a larger more clinically relevant margin of -5 points among children with completely off-ended fractures. Complications and serious adverse events were summarised in a safety (as-treated) population defined by treatment received. A within-trial economic evaluation was undertaken from the perspective of the UK National Health Service (NHS) and Personal Social Services over a 12-month time period. The trial was registered with the ISRCTN registry, ISRCTN10931294, recruitment is complete and extended follow-up to 3-years post-randomisation is ongoing. FINDINGS: Between Aug 11, 2020, and May 30, 2024, 1227 children were screened for eligibility across 49 UK hospitals. 477 children were excluded (54 met exclusion criteria and 423 did not enter the study, the majority for lack of clinical or parental equipoise). 750 participants were randomly assigned, 375 to the non-surgical casting group and 375 to the surgical reduction group. 456 (61%) participants were male, 294 (39%) were female, and the median age of participants was 7·9 years (IQR 6·5-9·5). 329 (44%) of the 750 participants had completely off-ended fractures. Primary outcome data were collected from 640 (85%) participants. At 3 months post-randomisation, the mean PROMIS Upper Extremity score was 44·9 (SD 8·7) in the non-surgical casting group and 46·6 (8·8) in the surgical reduction group (adjusted mean difference -1·64 [95% CI -2·84 to -0·44]), with the confidence interval favouring surgical reduction but extending beyond the prespecified non-inferiority margin of -2·5 points. In children with completely off-ended fractures, findings were consistent with non-inferiority against the wider, prespecified margin for this group. Most complications within 8 weeks occurred in the surgical reduction group, including pressure damage (n=2), wound infections (n=6), scarring (n=5), and nerve irritation (n=1). During the 12-months of follow-up, refracture occurred in 13 participants (nine after non-surgical casting and four after surgical reduction). From an NHS and Personal Social Services perspective, non-surgical casting was associated with a significant reduction in mean cost per patient of £1665 (95% CI 1487 to 1843) and a marginal incremental reduction in quality-adjusted life-years (QALYs; -0·023 [95% CI -0·037 to -0·009]). The probability of non-surgical casting being cost-effective at the £20 000 and £30 000 per QALY threshold was 100%, indicating that the small short-term functional advantage of surgical reduction was not cost-effective. INTERPRETATION: The CRAFFT trial did not demonstrate non-inferiority of non-surgical casting at 3 months against a conservative margin; however, the observed difference in favour of surgical reduction was small, below thresholds that families considered meaningful, and did not persist beyond early recovery. Surgical reduction was associated with higher costs, early procedural complications, and only a modest improvement in cosmetic appearance, supporting consideration of a cast-first strategy for most children. FUNDING: National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (17/22/02) and the NIHR Oxford Biomedical Research Centre.
2. Permeable Janus cellulose electronics with an intrinsic rear filter enabled by laser-induced graphitization for microfluidic wearable biosensors.
This study introduces a permeable Janus cellulose electronic platform where the top layer is laser-graphitized into a cellulose-derived LIG electrode and the bottom layer remains cellulose serving as an intrinsic rear filter for fluid transport and particulate removal. The architecture enhances the sample–sensor interface in microfluidic wearable biosensors, addressing a key bottleneck in reliable on-skin biochemical sensing.
Impact: The method provides a materials-based solution to integrate sensing and filtration in a single permeable substrate, potentially improving robustness and accuracy of skin-interfaced biosensors relevant to dermatology and cosmetic monitoring.
Clinical Implications: While preclinical, the design could enable more reliable sweat/skin biomarker monitoring (e.g., hydration, inflammation) in dermatology and cosmetic science, reducing contamination artifacts and improving sample handling on skin.
Key Findings
- Introduces a permeable Janus cellulose electronic device fabricated via thickness-dependent laser-induced graphitization.
- Top cellulose is graphitized to form cLIG sensing electrodes, while the underlying cellulose acts as an intrinsic rear filter for sample transport and contaminant removal.
- Improves the fluid-to-sensor interface for microfluidic wearable biosensors, addressing sample-sensor reliability.
Methodological Strengths
- Integrated materials architecture combining sensing electrodes and rear filtration in a single cellulose matrix.
- Scalable, laser-induced graphitization process enabling precise depth control for Janus structures.
Limitations
- Lack of in vivo human validation and quantitative performance metrics in the abstract.
- Potential challenges in long-term biocompatibility and mechanical durability on skin not addressed.
Future Directions: Benchmark analytical performance with biofluids (sweat/ISF), assess biocompatibility and durability during prolonged wear, and integrate catalysts (e.g., Pt) or enzymes to expand analyte coverage.
Integrating permeable electronics with microfluidics is an emerging strategy to improve the fluid-to-sensor interface in wearable biosensors, while achieving a reliable sample-sensor interface remains challenging. Here, we present an advanced permeable Janus cellulose electronic (PJCE) combining cellulose-derived laser-induced graphene (cLIG) electrodes with an intrinsic rear filter. PJCE is fabricated via a thickness-dependent laser-induced graphitization process, in which the top cellulose layer is graphitized to form the cLIG sensing electrode, while the underlying cellulose is preserved as a rear filter for sample transport and particulate contaminants removal. The cellulose matrix further enables loading of Pt
3. Carboxylesterase 2 as a potential molecular target for long-chain perfluoroalkyl carboxylic acids.
Protein target prediction and docking identified CES2 as a potential target of long-chain PFCAs. Enzyme assays and HepG2 studies showed micromolar PFCA inhibition of carboxylesterase activity, and mouse liver RNA-seq analysis revealed upregulation of Ces2a-associated genes, implicating CES2 inhibition as a mechanism contributing to PFAS toxicity.
Impact: Identifying CES2 as a molecular target integrates computational, biochemical, and transcriptomic evidence and has direct implications for xenobiotic and drug metabolism, informing regulatory decisions on PFAS in consumer products including cosmetics.
Clinical Implications: Potential CES2 inhibition by PFCAs raises concerns for drug–PFAS interactions and altered metabolism, suggesting need for risk assessment in populations with PFAS exposure, including cosmetic use and environmental sources.
Key Findings
- Target prediction and molecular docking nominate CES2 as a potential molecular target of long-chain PFCAs.
- In vitro enzyme assays and HepG2 experiments show micromolar inhibition of carboxylesterase activity by PFCAs.
- Public RNA-seq data from PFCA-treated mouse liver indicate overexpression of Ces2a-associated genes, supporting biological relevance.
Methodological Strengths
- Multi-modal approach integrating in silico prediction/docking with in vitro enzymology and cell-based assays.
- Use of public RNA-seq datasets for in vivo relevance triangulation.
Limitations
- Preclinical data without direct human in vivo validation.
- Inhibitory concentrations are micromolar; exposure–effect relevance at environmental levels remains uncertain.
Future Directions: Quantify CES2 inhibition across clinically relevant PFAS mixtures and concentrations, evaluate in vivo pharmacokinetic consequences, and investigate inter-individual susceptibility.
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are a broad and chemically diverse class of synthetic compounds widely used in industrial applications and consumer products. Human exposure to PFAS is widespread and occurs through multiple pathways, including drinking water, air, food, household dust, textiles, and cosmetics. PFAS have been linked to numerous adverse health effects and are a significant public health concern due to their extreme persistence in the environment, bioaccumulative properties, and broad biological activity. Despite growing evidence of PFAS toxicity, the molecular mechanisms underlying their biological effects remain incompletely understood, and the specific proteins involved have not been fully characterized. The aim of this study was to identify potential molecular targets for PFAS. Using protein target prediction tools, carboxylesterase 2 (CES2) was identified as a potential target for perfluoroalkylcarboxylic acids (PFCAs). These predictions were supported by molecular docking analyses. In vitro enzyme assays and experiments in HepG2 cells further support the potential inhibitory effects of PFCAs on carboxylesterase activity at micromolar concentrations. Furthermore, analysis of publicly available RNA-seq data from liver tissue of mice treated with PFCAs revealed overexpression of genes associated with Ces2a, the murine homologue of human CES2. These results suggest that PFCAs may contribute to adverse health effects, in part, through inhibition of CES2, a key enzyme involved in xenobiotic detoxification, drug metabolism, lipid metabolism, and energy homeostasis.